From unexpected diagnosis to DIAGNODE-3 participant
Katie Howell was diagnosed with type 1 diabetes last year at age 25. Now, she's the first DIAGNODE-3 trial participant…
Medical Affairs: Closing the gap between access and adoption
Breakthrough T1D's new Medical Affairs unit will address the numerous challenges contributing to the slow adoption of groundbreaking T1D therapies.
A behind-the-scenes look at DIAGNODE-3: Phase 3 clinical trials of Diamyd® for T1D
DIAGNODE-3 is a phase 3 clinical trial of the disease-modifying therapy Diamyd® that aims to preserve insulin-producing beta cells.
2024 greatest T1D hits: A glance at this year’s achievements
While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures…
Breakthrough T1D shares the latest research at ISPAD
At the 2024 International Society for Pediatric and Adolescent Diabetes (ISPAD) Conference in Lisbon, Portugal, the world’s leading diabetes researchers,…
Breakthrough T1D and the Nobel Prizes: Connected!
It’s early October, which means the Nobel Prizes are being awarded in several categories. These prestigious awards recognize outstanding contributions…
Powering research breakthroughs
We invest in the most promising research to turn ideas into life-changing therapies and lead the way to cures.
What Drug Will Be the Next Tzield?
In 2023 alone, there have been several important papers published on disease-modifying therapies (DMT) for type 1 diabetes. This blog…
FDA-Approved Immune Therapy Shows Benefit in Newly Diagnosed
In a Breakthrough T1D-funded clinical trial and published in the New England Journal of Medicine, baricitinib preserved beta cell function…
Results Are Out: Tzield Benefits Newly Diagnosed Individuals
A new study published in the New England Journal of Medicine shows Tzield can preserve beta cell health in certain…
